ArticleInternational journal of cancer2018
CLDN18.1 attenuates malignancy and related signaling pathways of lung adenocarcinoma in vivo and in vitro.
Abstract read
In one paragraph
Article in International journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review.Frontiers in aging neuroscience · 2021Pooled it
- Claudin-18.2: Molecular mechanisms to clinical translation in solid tumors (Review).Oncology letters · 2026Review
- Clinical overall survival prediction and disease characteristics of locally advanced non-small cell lung cancer: an integrated analysis based on the SEER and TCGA databases.Translational cancer research · 2026Article
- Claudin proteins as emerging therapeutic targets for solid tumours.Nature reviews. Cancer · 2026Review
- Single-cell eQTL mapping reveals cell-type-specific genetic regulation in lung cancer.Cell genomics · 2026Article
- Investigating the role of oncogenic FAM83A as a prognostic biomarker in lung adenocarcinoma: Insights from smoker and non-smoker cohorts.Journal, genetic engineering & biotechnology · 2025Article
- Novel Claudin18.2-Targeted Therapies in Gastrointestinal Tumors.ACS omega · 2025Review
- Review
- Claudin Proteins: Their Potential Role in Obesity and Adipose Tissue Signaling, Physiology and Disease.Nutrients · 2025Review
- Article
- Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 Study.Cancer science · 2025Article
- Prognostic role of claudin-18.2 in intrahepatic cholangiocarcinoma.Virchows Archiv : an international journal of pathology · 2025Article
- Biophysical basis of tight junction barrier modulation by a pan-claudin-binding molecule.PNAS nexus · 2025Article
- TLR7: A Key Prognostic Biomarker and Immunotherapeutic Target in Lung Adenocarcinoma.Biomedicines · 2025Article
- Tight junctional protein family, Claudins in cancer and cancer metastasis.Frontiers in oncology · 2025Review
- The preclinical discovery and development of zolbetuximab for the treatment of gastric cancer.Expert opinion on drug discovery · 2024Review
- Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian.Cancers · 2024Review
- Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer.Frontiers in oncology · 2024Review
- The small protein LINC01547-ORF inhibits colorectal cancer progression by regulating the CLDN18-FAK-AKT axis.American journal of cancer research · 2024Article
- Claudin18.2 expression in pulmonary mucinous adenocarcinoma.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Jiao LuoDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.ORCID 0000-0002-9204-8102
Nyam-Osor ChimgeDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Beiyun ZhouDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Per FlodbyDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Alessandra CastaldiDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Amy L FirthDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Yixin LiuDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Hongjun WangDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Chenchen YangNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.
Crystal N MarconettNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.
Edward D CrandallDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Ite A OffringaNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.
Baruch FrenkelNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.
Zea BorokDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.ORCID 0000-0001-8673-8177
University of Southern California · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MUSC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4MUSC RESEARCH CENTER FOR LIVER DISEASES: PILOT PROGRAMSP30DK048522 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAPLOWITZ, NEIL · 1995 to 2020
$21.8MBeyond the Barrier: Alveolar Epithelial Cell Biology in Health and DiseaseR35HL135747 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BOROK, ZEA · 2017 to 2023
$6.8MRole of Chaperone GRP78 and Mitochondrial Dysfunction in ER Stress-Mediated Pulmonary FibrosisR01HL114959 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ANN, DAVID K., ZHOU, BEIYUN · 2013 to 2025
$4.2MMechanisms of Lung Development and InjuryR01HL095349 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MINOO, PARVIZ MINOO · 2009 to 2017
$3.6MEpigenetic profiling of human alveolar epithelial cells in health and diseaseR01HL114094 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BOROK, ZEA, OFFRINGA, ITE A · 2011 to 2015
$3.3MSex Steroids and Runx Signaling in BoneR01DK071122 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI FRENKEL, BARUCH · 2005 to 2013
$2.5MMetabolites, Sickle Cell Disease, and Novel TherapeuticsR01HL113574 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI XIA, YANG · 2013 to 2016
$1.5MRunx Proteins and Sex Steroid Signaling in BoneR56DK071122 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI FRENKEL, BARUCH, SCHONES, DUSTIN EDWARD · 2009 to 2017
$603kConfocal Microscopy Imaging SystemS10RR022508 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI OOKHTENS, MURAD · 2007 to 2007
$415kNCI NIH HHS P30 CA014089NCI NIH HHS P30 CA016672NCRR NIH HHS S10 RR022508NHLBI NIH HHS R01 HL095349NHLBI NIH HHS R01 HL113574NHLBI NIH HHS R01 HL114094NHLBI NIH HHS R01 HL114959NHLBI NIH HHS R35 HL135747NIDDK NIH HHS P30 DK048522NIDDK NIH HHS R01 DK071122NIDDK NIH HHS R56 DK071122
Abstract
Claudins are a family of transmembrane proteins integral to the structure and function of tight junctions (TJ). Disruption of TJ and alterations in claudin expression are important features of invasive and metastatic cancer cells. Expression of CLDN18.1, the lung-specific isoform of CLDN18, is markedly decreased in lung adenocarcinoma (LuAd). Furthermore, we recently observed that aged Cldn18
Indexed as
Adenocarcinoma of LungAnimalsBlotting, WesternCell ProliferationClaudinsDNA MethylationHumansIntracellular Signaling Peptides and ProteinsLung NeoplasmsMiceMice, KnockoutNeoplasm InvasivenessNeoplasm MetastasisPhosphorylationPromoter Regions, GeneticProto-Oncogene Proteins c-aktClaudinsCLDN18 protein, humanIntracellular Signaling Peptides and ProteinsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-yesReceptor, IGF Type 1Trans-ActivatorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsWWTR1 protein, humanYES1 protein, humanAKTIGF-1 receptorlung alveolar epithelial type II cellsxenograftYAP/TAZ
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.